Three years of treatment with tirzepatide in persons with obesity and prediabetes resulted in substantial and sustained weight reduction and a markedly lower risk of progression to type 2 diabetes than that with placebo.
The new biosynthetic peptide development platform is an innovative platform based on advanced technologies and methods, aiming at accelerating the research and manufacturing process of peptide drugs. This platform combines technologies from the fields of biosynthesis, genetic engineering, protein engineering and chemical synthesis, with the goal of providing efficient, controllable and customizable solutions for peptide drug development.
Patients treated with CagriSema achieved a superior weight loss of 22.7% after 68 weeks, 40.4% of patients who received CagriSema reached a weight loss of 25% or more after 68 weeks.
The 2024 Lasker~DeBakey Clinical Medical Research Award honors three scientists for their discovery and development of GLP-1-based drugs that have revolutionized the treatment of obesity. Joel Habener (Massachusetts General Hospital) and Svetlana Mojsov (The Rockefeller University) discerned the physiologically active form of the hormone, and Lotte Bjerre Knudsen (Novo Nordisk) turned it into medications that promote weight loss.
info@highrui.com
Room 1522, Building 21, Lanqi road, Qinhuai District, Nanjing, Jiangsu
